作者
Edward Abraham, Richard Wunderink, Henry Silverman, Trish M Perl, Stanley Nasraway, Howard Levy, Roger Bone, Richard P Wenzel, Robert Balk, Randy Allred, James E Pennington, Janice C Wherry, Paul Bellamy, Henry Cryer, Ronald Busuttil, Drew Winston, Cindy Perry, Kenneth V Leeper, Carol Jones, Michael Martin, Pam Tuma, Ian Baird, Jane Brooks, Rebecca Baird, Sigfrido Rangel, Nancy Wagner, Michele Costigan, Guillermo Gutierrez, Phillip Johnson, Cinda Clark, Cindy Grover, Peter C Gay, Jim Stekelberg, Phillip Van Steinburg, Jorge Ortiz, Pamel Sigel, Anne Murphy, William Lahey, Joseph Plouffe, Robert J Fass, Jane Russell, Richard E Crowell, Steven Q Simpson, Mary Neidhart, Mark Dunn, Louis Saravolatz, Neena Griffin, Tobias C Samo, Victor Feinstein, Kay Doyle, Collette Tuttle, Richard Brown, Jay Steingrub, Mary Jo Safford, Alfred Bacon, William Holloway, Shirly Amato, Fay Schneider, Galen B Toews, Robert Fekety, Julie Kugler, Janet Hampton, Faroque A Kahn, Ashok Karnik, Michael Niederman, Burke Cunha, Nancy Clare, James Leatherman, Philip K Peterson, Charlotte Doak, Laurie Zimmerman, Jonathan E Gottlieb, Lisa Stokes, Curtis Sessler, Karen Deere, Debbie Gloskey, David Longworth, Laura Liucchi, Charles Strange, Ruth Oser, David Gilbert, James E Leggett, Kay Waite, Nicolas V Christou, Sheldon Magder, Micheline Bonneau, James S Tan, Thomas File, Sara Jane Salstrom, Sydney Eaton, Gary Garber, Gynne Jones, Isabel Seguin, Anthony W Chow, Martin Tweeddale, Linda Schwartz, George Pankey, Joan Vollenweider, Harold Neu, Glenda Garvey, Patricia Dorney, Richard A Jacobs, Michael Bernstein, Jackie Octavio, Brian Schillinger, Thomas Iberti, James Russell, John Sheagren, Donald Craven, Lona Poole, Warren Myers, Maureen Ash, Nancy Czarny, George Arcieri, Gary Koch, Johann Prove, Daniel Remick, Michael Fournel
发表日期
1995/3/22
期刊
Jama
卷号
273
期号
12
页码范围
934-941
出版商
American Medical Association
简介
Objective
—To evaluate the efficacy and safety of anti—tumor necrosis factor α monoclonal antibody (TNF-α MAb) in the treatment of patients with sepsis syndrome.
Design
—Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial.
Setting
—A total of 31 hospitals in the United States and Canada.
Patients
—There were 994 patients with sepsis syndrome enrolled in this clinical trial, and 971 patients were infused with the study drug.
Intervention
—Patients were prospectively stratified into shock or nonshock groups and then randomized to receive a single infusion of 15 mg/kg of TNF-α MAb, 7.5 mg/kg of TNF-α MAb, or placebo. Patients received standard aggressive medical and surgical care during the 28-day postinfusion period.
Outcome Measure
—Twenty-eight-day all-cause mortality.
Results
—The distribution of variables describing demographics, organ system dysfunction or failure …
引用总数
学术搜索中的文章
E Abraham, R Wunderink, H Silverman, TM Perl… - Jama, 1995